SARS-CoV-2 Induces Lymphocytopenia by Promoting Inflammation and Decimates Secondary Lymphoid Organs

Qun Xiang†, Zeqing Feng†, Bo Diao‡, Chao Tu‡, Qinghua Qiao¶, Han Yang†, Yi Zhang†, Gang Wang§, Huiming Wang∥, Chenhui Wang†, Liang Liu¶, Chingsong Wang‡, Longding Liu‡, Rong Chen†* and Yongwen Chen†*

1 Institute of Immunology, PLA, Third Military Medical University, Chongqing, China, 2 Department of Medical Laboratory Center, General Hospital of Central Theater Command, Wuhan, China, 3 Department of Pathology, Jinjintan Hospital, Wuhan, China, 4 Pingshangshan Medical District, The 989th Hospital of the PLA Joint Logistic Support Force, Pingshangshan, China, 5 Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, China, 6 Department of Forensic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 7 Department of Pathology, 989th Hospital of PLA, Luoyang, China, 8 Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, China

While lymphocytopenia is a common characteristic of coronavirus disease 2019 (COVID-19), the mechanisms responsible for this lymphocyte depletion are unclear. Here, we retrospectively reviewed the clinical and immunological data from 18 fatal COVID-19 cases, results showed that these patients had severe lymphocytopenia, together with high serum levels of inflammatory cytokines (IL-6, IL-8 and IL-10), and elevation of many other mediators in routine laboratory tests, including C-reactive protein, lactate dehydrogenase, α-hydroxybutyrate dehydrogenase and natriuretic peptide type B. The spleens and hilar lymph nodes (LNs) from six additional COVID-19 patients with post-mortem examinations were also collected, histopathologic detection showed that both organs manifested severe tissue damage and lymphocyte apoptosis in these six cases. In situ hybridization assays illustrated that SARS-CoV-2 viral RNA accumulates in these tissues, and transmission electronic microscopy confirmed that coronavirus-like particles were visible in the LNs. SARS-CoV-2 Spike and Nucleocapsid protein (NP) accumulated in the spleens and LNs, and the NP antigen restricted in angiotensin-converting enzyme 2 (ACE2) positive macrophages and dendritic cells (DCs). Furthermore, SARS-CoV-2 triggered the transcription of Il6, Il8 and Il1b genes in infected primary macrophages and DCs in vitro, and SARS-CoV-2-NP+ macrophages and DCs also manifested high levels of IL-6 and IL-1β, which might directly decimate human spleens and LNs and subsequently lead to lymphocytopenia in vivo. Collectively, these results demonstrated that SARS-CoV-2 induced lymphocytopenia by promoting systemic inflammation and direct neutralization in human spleen and LNs.

Keywords: SARS-CoV-2, COVID-19, macrophages, dendritic cells, lymphocytopenia, spleen, lymph nodes
INTRODUCTION

In December 2019, clusters of patients with pneumonia of unknown etiology were reported by local health facilities in Wuhan, Hubei Province, China. Later, the causative agent responsible for this mysterious pneumonia was officially named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on the Taxonomy of Viruses, and the disease it caused was designated as coronavirus disease 2019 (COVID-19) (1). According to the daily reports of the WHO, the SARS-CoV-2 pandemic has caused 102,458 laboratory confirmed cases and 4,849 deaths in China as of 18th March 2021. Meanwhile, the number of confirmed COVID-19 cases and fatalities around the world has reached 121,719,887 and 2,687,905, respectively (2). The typical symptoms of COVID-19, including fever, cough, shortness of breath and pneumonia, are very common in mild cases, while acute respiratory distress syndrome (ARDS), acute cardiac injury and lymphocytopenia are also prevalent, especially in aged and critically ill patients, implying that SARS-CoV-2 affects various organs (3, 4).

It has been reported that SARS-CoV-2 interacts with human angiotensin-converting enzyme 2 (ACE2) via the spike protein for human to human transmission. Overwhelming data have shown that the ACE2 protein has a wide tissue distribution, including in the lung, liver, stomach, ileum, colon and kidney (5). Single-cell RNA sequencing of 13 human tissues showed that Ace2 mRNA is mainly expressed in lung AT2 cells, liver cholangiocytes, colon colonocytes, esophagus keratinocytes, ileum epithelial cells (ECs), rectum ECs, stomach ECs and kidney proximal tubules (6). However, no data are available with regards to whether some types of immune cells or cells in the secondary lymphoid organs are positive for ACE2, or whether this leads to SARS-CoV-2 infection and subsequent lymphocytopenia in COVID-19 patients. Therefore, deciphering SARS-CoV-2 infection in immune organs is critical for understanding virus-mediated lymphocytopenia and possibly identifying methods to boost the number of lymphocytes and enhance host immunity.

In this report, we retrospectively reviewed the clinical data from 18 deceased COVID-19 patients who were admitted to the First Pneumonia Ward of Huoshenshan Hospital from February 5th to April 10th, 2020 and post-mortem analysis was executed by the Ethics Commission of the Jinyintan Hospital (KY-2020-15.01).

METHODS

Data Collection and Definitions

Electronic medical records from 18 deceased COVID-19 patients who were admitted to the First Pneumonia Ward of Huoshenshan Hospital from February 5th to April 10th, 2020 were collected and retrospectively analyzed. Patients died within 3 days of the date corresponding to data. Diagnosis of COVID-19 was based on the New Coronavirus Pneumonia Prevention and Control Program (6th edition) published by the National Health Commission of China. All of the patients were laboratory-confirmed positive for SARS-CoV-2 by use of quantitative RT-PCR (qRT-PCR) of throat swab samples. Primers and probes targeting the SARS-CoV-2 nucleocapsid gene were used and the sequences were as follows: forward primer, 5'-TCAGAATGCAATCTCCCAAACGCT-3'; reverse primer, 5'-AAAGGTCCACCCGATAATGGA-3'; and the probe, 5'-CY5-CTAGTTAC ACTAGCCATCCCTACTGC-3'-BHQ1. Conditions for the amplifications were 50°C for 15 minutes and 95°C for 3 minutes, followed by 45 cycles of 95°C for 15 seconds and 60°C for 30 seconds. Three investigators (Dr. Yi Zhang, Dr. Qinghua Qiao and Dr. Bo Diao) directly collected the electronic medical records and independently reviewed the data collection forms to verify data accuracy.

COVID-19 Post-Mortem Autopsies

The spleens and the hilar LNs from six COVID-19 patients with post-mortem examinations were collected, these deceased COVID-19 patients were admitted to Jinyintan Hospital in Wuhan, Hubei Province, China. Due to the special infection-control precautions for handling deceased subjects with COVID-19, post-mortem examination was performed in a designated pathology laboratory. The deceased patients were taken for post-mortem examination immediately (4 cases) or kept at -20°C until post-mortem analysis was carried out within 24 hours of death (2 cases). The spleens and the hilar LNs were collected by standard examination at autopsy. Collection of other medical data for these six cases with post-mortem examinations was executed by two investigators (C Tu and R Chen). The spleens and LNs were also collected from two trauma victim autopsies (male, 65 years old; female, 62 years old), one biopsy from an EBV-infected patient (male, 47 years old), and one biopsy from a patient with HBV-related acute-on-chronic liver failure (HBV-ACLF; male, 60 years old) who also manifested ARDS. This study was approved by the Ethics Commission of the Jinyintan Hospital (KY-2020-15.01).

H&E Staining

Briefly, paraffin-embedded tissue blocks were cut into 2.5 μm slices and mounted onto poly-lysine-coated glass slides. Sections were incubated with hematoxylin for 5 min, and then after 1 min of dehydration with 100% alcohol, sections were further treated with eosin for 30 sec. Sections were then mounted and viewed using a light microscope (Zeiss Axioflap 2, Berlin, Germany). Histopathological results were independently assessed by two blinded investigators (Dr. Changsong Wang and Dr. Rong Chen).
**TUNEL Staining**

Cellular apoptosis was measured using an *In Situ* Cell Death Detection Kit, POD, according to the manufacturer’s instructions (#11684817910, Roche, Berlin, Germany). The proportion of terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL)-positive nuclei in spleens and LNs were determined through image analysis of the histological sections.

**IHC**

The protocol for immunohistochemistry was published previously (7). Briefly, paraffin-embedded tissue blocks were cut into 2.5 μm sections and mounted on poly-L-lysine-charged glass slides. Sections were de-waxed and rehydrated, and antigen retrieval was performed by microwaving in 10 mM citrate buffer (pH 6.0). Endogenous peroxidase activity was blocked by incubation with a solution of 0.5% hydrogen peroxide (H₂O₂) in 50% methanol for 10 min. The sections were then incubated in 2% BSA plus 0.1% Nonidet P-40 in PBS for 1 h at RT to block non-specific binding. Sections were then incubated overnight at 4°C with primary antibodies including anti-SARS-CoV-2 nucleocapsid protein (NP) (#clone ID: 019, 1:200, rabbit IgG1; Sino Biological, Beijing, China), anti-TRMPSS2 (#204314-T08, 1:100, rabbit IgG1; Sino Biological), anti-SARS-CoV-2 NP (#ab273434, 1:500, mouse monoclonal 6H3; Abcam, Shanghai, China), anti-SARS-CoV-2 spike glycoprotein (S) (#ab273433, 1:500, mouse monoclonal 1A9; Abcam), anti-AE2 (#clone ID: 10108-RP01, 1:200, rabbit IgG1; Sino Biological), anti-Fasl. (#sc-834, 1:300, rabbit IgG1; Santa Cruz, San Francisco, CA, USA), anti-IL-1β (#ab9722, rabbit IgG1, Abcam), anti-IL-6 (#12153, Rabbit mAb, CST), rabbit IgG1 isotype (#10500C, 1:200; ThermoFisher, Waltham, MA, USA) or mouse IgG1 isotype (#02-6100, 1:200; ThermoFisher) antibodies. After washing, sections were incubated with the corresponding secondary antibodies (polyclonal goat anti-rabbit IgG/biotinylated, #00070204, 1:200, DAKO, Copenhagen, Denmark or polyclonal rabbit anti-mouse IgG/biotinylated, #00070978, 1:200, DAKO) for 1 h at RT. The Vecta-stain ABC kit (#ZD0810, Vector Laboratories, San Diego, CA, USA) was used for the avidin-biotin complex method according the manufacturer’s instructions. Peroxidase activity was visualized with the DAB substrate kit (#ab64238; Abcam), and brown coloration of tissues represented positive staining. The sections were lightly counterstained with hematoxylin, and brown coloration of tissues represented positive staining. The virus-like particles were observed under a JEM1200 transmission electron microscope (Jeol, Tokyo, Japan).

**Immunofluorescent Double Staining**

Sections were incubated at 4°C overnight with primary mouse originated antibodies including anti-SARS-CoV-2 NP (#ab273434, 1:500, mouse IgG1; Abcam), anti-AE2 (#MA5-31395, clone ID: CLA035, 1:400, mouse IgG1; Invitrogen), anti-CD68 (#MAB11303, clone KP1, 1:300, mouse IgG1; Bio-RAD), anti-CD169 (#346020, clone ID: 7-239, 1:200, mouse IgG1; Biolegend), anti-B220 (#MAB1100, clone ID: 123C3, 1:100, mouse IgG1; Bio-RAD), anti-CD11c (#ab254183, clone ID: KB90, 1:200, mouse IgG1; Abcam), and anti-Fas (#48095942, 1:200, mouse IgG1; ThermoFisher), and rabbit originated antibodies including anti-SARS-CoV-2 NP (#clone ID: 019, 1:200, rabbit IgG; Sino Biological), anti-IL-1β (#ab9722, rabbit IgG1, Abcam) and anti-IL-6 (#12153, Rabbit mAb, CST). After washing with PBS (3 washes, 5 min per wash), sections were incubated with Alexa Fluor® 555-conjugated goat anti-rabbit IgG antibodies (#ab150078, 1:200, Abcam) or Alexa Fluor® 488-conjugated goat anti-mouse IgG antibodies (#ab150078, 1:200, Abcam) for 1 h. Finally, the sections were incubated with 1 μg/ml DAPI (Sigma, St. Louis, MO, USA) for 10 min to stain the nuclei. Sections incubated with the appropriate isotype control antibodies and fluoroscently labelled secondary antibodies were used as negative controls. Results were analyzed using fluorescence microscopy (Zeiss Axioplan 2).

**TEM Assay**

Two hilar lymph nodes from 2 COVID-19 autopsies (case #1 and case #2) were collected and fixed with 2.5% glutaraldehyde in phosphoric buffer (pH 7.4), post-fixed with 1% osmate, dehydrated with gradient alcohol, embedded in Epon 812, and double-stained with uranium acetate and lead citromalic acid. The virus-like particles were observed under a JEM1200 transmission electron microscope (Jeol, Tokyo, Japan).

**Detection of SARS-CoV-2 Viral RNA by ISH**

SARS-CoV-2 viral RNA *in situ* hybridization (ISH) in the spleens and LNs from three cases of fatal COVID-19 was performed using RNAscope® Probe-V-nCoV2019-S (#848561, ACD, Newark, CA) directed against SARS-CoV-2 targeting 21631-23303 of NC_045512.2 and RNAScope® Probe-V-nCoV2019-S-sense (#845701, ACD). A negative control probe targeting the bacterial gene peptidylprolyl isomerase B (PPIB) was used for RNA integrity (#845701, ACD). A negative control probe targeting the bacterial gene peptidylprolyl isomerase B (PPIB) was used for RNA integrity (#313901, ACD) as positive control. The RNAscope® 2.5 HD Reagent Kit-RED (#322350, ACD) was utilized per the manufacturer’s instructions. Briefly, the spleen and LN tissue retrieval was performed at 95°C for 20 min, followed by incubation with the RNAscope protease for 15 min at 40°C. Probes were added and hybridized was carried out for 3 h at 42°C using the following protocol: AMP1 3′-diaminobenzidine (DAB) was incubated for 30 min, AMP2 DAB for 15 min, AMP3 DAB for 30 min, AMP4 DAB for 15 min, AMP5 DAB for 30 min, and AMP6 DAB for 15 min, followed by incubation with DAB for 20 min. Sections were counterstained with periodic acid-Schiff. Here, SARS-CoV-2 viral RNA was also detected in the spleens of trauma victims.
A similar protocol was also used to detect viral RNA in macrophages and DCs with or without SARS-CoV-2 infection in vitro.

**Cells and SARS-CoV-2 Infection In Vitro**

Peripheral blood mononuclear cells (PBMCs) were isolated from fresh blood samples of healthy donors using human peripheral lymphocytes separation medium (#LTS1077-1, TBD, Tianjin Haoyang) according to recommended protocol. Isolated PBMCs were then allowed to adhere to cell plates pre-coated with poly-D-lysine. After 2 h of adhesion, non-adherent cells were washed away with pre-warm PBS. Adherent monocytes were cultured in RPMI-1640 (#C11875500BT, Gibco) supplemented with 10% FBS (#10099141C, Gibco) and 1% Penicillin-Streptomycin (#10378016, Gibco) at 37°C with 5% CO₂ atmosphere. Monocytes-derived macrophages (MDMs) were differentiated by providing human granulocyte-macrophage colony-stimulating factor (hGM-CSF, #300-03, 50 ng/mL, Peprotech) for 6 days, while Monocytes-derived dendritic cells (MoDCs) were differentiated by adding hGM-CSF (#300-03, 50 ng/mL, Peprotech) and human interleukin-4 (hIL-4, #200-04, 25 ng/mL, Peprotech) for 6 days. The SARS-CoV-2 virus was provided by Prof. Liu reported previously (8). For virus infection, MoDCs and MDMs were replaced with fresh RPMI-1640 and then infected with SARS-CoV-2 at a MOI = 0.1 for 2 h. After virus absorption, cells were washed with pre-warmed RPMI-1640 twice and maintained in RPM1640 containing 2% FBS for 24 h before further measurement.

**Quantitative RT-PCR**

Total RNA was extracted from SARS-CoV-2-infected MDMs and MoDCs using TRizol reagent (#15596026, Invitrogen) according to the manufacturer’s instructions. First-strand cDNA was synthesized with the PrimeScript RT reagent Kit with gDNA Eraser (#RR047A, Takara). The primers specific for target gene were designed by Primer 5.0 software and confirmed by using BLAST program in NCBI. The expression of target genes was quantified by using the TB Green Premix Ex Taq II (#RR820, Takara) on the CFX96 real-time PCR thermal cycle instrument (Bio-Rad). The expression of each gene was normalized to the expression of HPRT housekeeper gene, and the fold change of gene expression was further calculated using 2−ΔΔCt method. Primer sequences used were showed in **Table S3**.

**Statistical Analysis**

For all analysis, two-tailed, unpaired Student’s t-tests with a 95% confidence interval performed on graphs generated in GraphPad Prism GraphPad Prism version 8.0 (GraphPad Software, Inc., San Diego, CA, USA) were used. Error bars represent the SEM. p<0.05 was considered a statistically significant difference. All results shown are representative of at least three separate experiments.

**RESULTS**

**Lymphocytopenia and Inflammation Are Common in Deceased COVID-19 Patients**

We retrospectively analyzed the cases of 18 deceased COVID-19 patients who were admitted to the Intensive Care Unit (ICU) of Huoshenshan Hospital in Wuhan, Hubei Province. These patients included 14 (77.8%) males and 4 (22.2%) females, with an average age of 74.83 years. A total of 13 (72.2%) patients were over 70 years old and 11 patients had at least one underlying disease, including hypertension (n = 9; 50.0%), type-1 diabetes (n = 4; 22.2%) (**Table S1**). All of these patients suffered from ARDS based on available arterial blood gas (ABG) analysis carried out when their data was collected. Other clinical symptoms included dyspnea (n = 16; 88.9%), fever (n = 14; 77.8%), cough (n = 11; 61.1%), fatigue (n = 10; 55.6%), respiratory failure (n = 7; 38.9%), myalgia (n = 3; 16.7%) and expectoration (n = 2; 11.1%). Less common complications included respiratory failure (n = 7; 38.9%), acute cardiac injury (n = 6; 33.3%), acute kidney injury (n = 5; 27.8%), secondary infection (n = 4; 22.2%) and acute liver injury (n = 1; 5.6%). These patients were given empirical antimicrobial treatment including moxifloxacin and/or cephalosporin, as well as antiviral therapy like oseltamivir and/or ganciclovir. All cases received corticosteroid (methylprednisolone) during the course of hospitalization. A total of 16 (88.9%) cases required non-invasive mechanical ventilation continuous positive airway pressure (CPAP). The average number of hospital days was 41.56 days from the onset of illness to death (**Table S1**).

We next retrospectively reviewed the clinical and immunological data of these patients, and all patients died within 3 days of the date corresponding to data. The mean absolute numbers (13.51 x 10⁹/L) of white blood cells (WBC) in these patients were 1.42 folds higher than the upper limit of normal range (ULN). A total of 17 patients had lower blood platelet counts (mean value: 99.76 x 10⁹/L), erythrocyte counts (mean value: 3.04 x 10¹²/L) and serum hemoglobin concentration (mean value: 95.78 g/L) than the corresponding lower limit of normal ranges (LLN). However, 14 (77.8%) patients had both high percentage (mean value: 88.31%) and increased absolute number (mean value: 12.33 x 10⁹/L) of neutrophils (**Table 1**). A total of 17 (94.4%) patients had lymphocytopenia and the mean lymphocyte counts were 0.64 x 10⁹/L, which was below the LLN. Importantly, depletion of T cells (mean value: 3.95 x 10⁹/L) was more prominent than that of B cells (mean value: 11.31 x 10⁹/L) in these patients (**Table 1**), demonstrating that lymphocytopenia is the main feature of severe COVID-19 disease.

The dysregulation of pro-inflammatory cytokines can induce lymphocyte depletion (3, 9), and high levels of serum IL-6 and IL-8, as well as IL-10, were observed in these fatal cases. In particular, the average serum IL-6 concentration reached 2869.4 pg/mL, which is 22.01 folds above the ULN. Additionally, the mean serum level of IL-10 was also 1.77 folds higher than the ULN. Although some COVID-19 cases have very high serum concentration of IL-17, IL-1β and TNF-α, the average levels of these cytokines did not change dramatically compared to normal values (**Table 1**). Furthermore, enhancement of C-reactive protein (CRP, mean value 102.81 mg/L, 25.7 folds above the ULN), D-dimer (mean value 3.31 mg/L, 6.02 folds above the ULN), direct bilirubin (DBIL, 58.58 μmol/L, 7.32 folds above the ULN), blood urea nitrogen (urea, 19.78 μmol/L, 2.47 folds above the ULN), lactate...
TABLE 1 | Laboratory findings of perished patients with COVID-19.

| Cells in blood | Cytokines | Alarmins |
|----------------|-----------|----------|
| Platelet counts, x10^{12} | Erythrocyte counts, | Hemoglobin (g/dL) |
| Neutrophils | Neutrophil count, x10^{6}/L | | |
| Monocyte count, x10^{9}/L | T cell count, x10^{9}/L | | |
| B cell count, x10^{8}/L | | | |
| IL-6 (pg/mL) | IL-17 (pg/mL) | IL-8 (pg/mL) |
| IL-10 (pg/mL) | TNF-α (pg/mL) | CRP (mg/L) |
| DBIL (umol/L) | PCT (ng/mL) | D-imerin (ng/mL) |

| #2 | 9.3 | 211 | 2.64 | 94 | 89.9 | 8.31 | 4.4 | 0.41 | 5.6 | 0.52 | 3.74 | 10.09 | 298.84 | 4.05 | 1.28 | 3.04 | 49.89 | 11.26 | 0.03 | 15.75 | 1.01 | 8.2 | 13.83 | 389.7 | 304.3 | 0.11 |
| #3 | 10.6 | 110 | 2.9 | 90 | 93.8 | 9.94 | 2.1 | 0.22 | 4.1 | 0.44 | 2.05 | 5.76 | 3720.89 | 13.67 | 2.02 | 4.11 | 559.41 | 24.72 | 1.30 | 145.5 | 4.01 | 9.1 | 18.68 | 446.6 | 391.6 | 11.53 |
| #7 | 5.5 | 81 | 3 | 94 | 87.5 | 4.81 | 5.3 | 0.29 | 5 | 0.28 | 1.63 | 1.40 | 1466.34 | 2.42 | 4.57 | 3.24 | 18.37 | 2.74 | 3.13 | 101.8 | 2.52 | 21.8 | 18.7 | 341 | 293.1 | 2.15 |
| #8 | 11.7 | 120 | 3.27 | 102 | 91.9 | 10.75 | 2.7 | 0.32 | 5 | 0.58 | 3.62 | 13.40 | 14761.35 | 1.18 | 4.57 | 3.31 | 25.25 | 4.10 | 2.00 | 81.3 | 3.73 | 39.3 | 11.73 | 389.7 | 304.3 | 0.11 |
| #10 | 76.2 | 183 | 2.85 | 90 | 96.5 | 73.51 | 1.8 | 1.36 | 1.0 | 0.73 | 4.42 | 3.50 | 65.28 | 0.00 | 26.98 | 4.54 | 96.81 | 6.64 | 2.41 | 113.35 | 4.63 | 11.1 | 27.90 | 71.0 | 8.84 | 14.1 | 1.76 | 13.8 | 1.72 |
| #14 | 36.6 | 235 | 2.43 | 74 | 97.4 | 35.61 | 1.1 | 0.39 | 1.4 | 0.52 | 3.78 | 1.77 | 395.59 | 15.43 | 35.50 | 3.84 | 251.92 | 26.11 | 4.57 | 64.70 | 1.27 | 7.8 | 2.58 | 370.90 | 289.70 | 0.36 |
| #15 | 11.5 | 10 | 2.25 | 72 | 95.1 | 10.96 | 2.1 | 0.24 | 2.5 | 0.29 | 2.30 | 3.86 | 356.30 | 0.00 | 29.67 | 2.85 | 61.80 | 6.09 | 2.41 | 48.79 | 2.32 | 34.2 | 3.80 | >1000.00 | >1000.00 | 1.98 |
| #17 | 8.6 | 57 | 4.34 | 115 | 96.3 | 8.28 | 1.5 | 0.13 | 2.1 | 0.18 | 1.02 | 4.95 | 371.2 | 7.86 | 2.93 | 4.06 | 52.75 | 52.56 | 1.23 | 122.41 | 12 | 5.8 | 9.33 | 347.90 | 294.20 | 0.56 |
| #18 | 21.3 | 64 | 2.24 | 68 | 90.6 | 19.31 | 4.3 | 0.92 | 3.4 | 0.72 | 3.79 | 25.92 | 415.90 | 5.94 | 0.56 | 2.34 | 92.04 | 7.26 | 0.35 | 161.53 | 2.85 | 2.3 | 23.61 | 351.30 | 297.50 | 1.65 |

Mean 13.51 99.76 3.04 95.78 88.30 12.33 3.42 0.35 7.06 0.64 3.95 11.32 2869.40 9.37 15.82 4.53 283.99 22.88 3.01 102.81 3.31 58.58 19.78 3.40

Normal range: 3.5-12.5 for LDH, 5-25 for HBDH, 1.2-2.8 for FasL, and 0.9-2.7 for TUNEL staining.

Collectively, these data suggest that lymphocytopenia and systemic inflammation are very common in patients that succumb to COVID-19.

SARS-CoV-2 Destroys Human Spleens and LNs

In addition to inducing circulating lymphocyte depletion by enhancing inflammation, SARS-CoV-2 might also promote lymphocytopenia by directly destroying human secondary lymphoid organs, since this virus is well known to be highly cytopathic. Therefore, the hilar LNs and spleens were collected from warm autopsies of six COVID-19 subjects. All of these deceased patients manifested severe lymphocytopenia, as demonstrated by extremely low lymphocyte counts. They were also given empirical antimicrobial treatment and antiviral therapy, and two cases even received corticosteroids during their course of hospitalization, none of them received extracorporeal membrane oxygenation (ECMO) treatment. Other clinical characteristics of these 6 deceased patients are shown in Table 2. H&E staining of lung tissues confirmed that the alveolar wall was thickened, and that telangiectasia, ecchymosis and strong inflammatory cell infiltration occurred, suggesting that SARS-CoV-2 worsens lung damage (Figure S1). Surprisingly, acute tissue damage and lymphocyte reduction occurred in all of the assessed hilar LNs and spleens. The LNs were congested, hemorrhagic and accompanied by subcapsular sinus histiocytosis, some cases also showed an enlargement of the abdominal lymph nodes, which had reduced number of germinal centers. Moreover, the lymph follicles and paracortical areas in some patients were not fully identifiable, with necrotic and apoptotic lymphocytes being widely distributed. Similarly, all of the spleen tissues exhibited atrophy of the white pulp, with a complete loss in some cases. The red pulp was markedly congested, hemorrhagic, and the total lymphocyte counts were also significantly reduced (Figure 1A, Table 2), whereas, the spleens and LNs from trauma victims and HBV-ACLF patients and EBV-infected patients normal morphologic structures. By contrast, the spleens and LNs from EBV-infected patients showed smaller lymphoid follicles, T zone proliferation and an enhancement of immunoblastic cells (Figure S2), demonstrating that SARS-CoV-2 causes severe damage in human spleens and LNs that is different from that in EBV and HBV infection.

In situ TUNEL staining showed that spleens and hilar LNs from COVID-19 autopsies manifested strong lymphocyte apoptosis, whereas, apoptotic cells in tissues from age- and gender-matched HBV-ACLF and EBV-infected patients and trauma victims were nearly undetectable (Figure 1B). Cell apoptosis is primarily mediated by Fas and Fas ligand (FasL) signaling (10). IHC showed that spleen and LN tissues from COVID-19 patients and controls have similar levels of FasL expression (Figure S3). Conversely, sections from COVID-19 autopsies manifested significantly higher levels of Fas than those of dehydrogenase (LDH, 366.17 IU/L, 1.46 folds above the ULN), α-hydroxybutyrate dehydrogenase (HBDH, 302.4 IU/L, 1.66 folds above the ULN) and procalcitonin (PCT, 3.4 ng/mL, 68 folds above the ULN) was also observed in most cases (Table 1). However, serum concentrations of other alarmins were not significantly different from normal values (Table S2).
TABLE 2 | The pathologic findings from COVID-19 patients undergoing postmortem examination.

| Case | #1 | #2 | #3 | #4 | #5 | #6 |
|------|----|----|----|----|----|----|
| Coexisting disorder | | | | | | |
| Hypertension | >10 yr | >10 yr | – | >10 yr | >5 yr | – |
| Coronary disease | – | >10 yr | – | – | – | – |
| Gout | – | – | – | – | Yes | – |
| Cause of death | ARDS | ARDS | ARDS | ARDS | ARDS | ARDS |
| SARS-CoV-2 confirmed by PCR | Yes | Yes | Yes | Yes | Yes | Yes |
| Corticosteroid | Yes | – | – | – | – | Yes |
| H&E staining | | | | | | |
| Congestion and hemorrhage | ++ | +++ | +++ | ++ | +++ | ++ |
| WP destruction or atrophy | ++ | +++ | +++ | ++ | +++ | ++ |
| Marginal areas disappearance | Yes | Yes | Yes | Yes | Yes | Yes |
| Lymphocyte depletion | Yes | Yes | Yes | Yes | Yes | Yes |
| Splicenic nodule atrophy | Yes | – | – | – | – | – |
| Interstitial fibrosis | Yes | – | – | – | – | – |
| Reduced number of GC | – | Yes | – | – | – | Yes |
| LNs | | | | | | |
| Congestion and hemorrhage | ++ | +++ | +++ | ++ | +++ | ++ |
| lymph follicle disappearance | Yes | Yes | Yes | Yes | Yes | Yes |
| histioyte hyperplasia | Yes | Yes | Yes | Yes | Yes | Yes |
| Eltangiectasia | Yes | Yes | Yes | Yes | Yes | Yes |
| Lymphocyte depletion | Yes | Yes | Yes | Yes | Yes | Yes |
| Immunohistochemistry (Nubers of positive cells/hpf) | | | | | | |
| SARS-CoV-2 NP in spleens | 72.5±10.43 | 15.75±2.75 | 71.83±17.58 | 16.75±4.35 | 63.5±27.74 | 67.25±14.37 |
| SARS-CoV-2 NP in LNs | 214.3±83.1 | 119.5±31.2 | 59.25±17.21 | 60.5±21.16 | 80.25±21.71 | 54±12.4 |
| IL-1β in spleens | 257±18.06 | 136.5±22.53 | 99.5±16.24 | 151.2±26.91 | 187±30.83 | 67.25±13.68 |
| IL-1β in LNs | 135.5±38.86 | 63.5±12.9 | 56±5.30 | 41±8.44 | 96.25±17.72 | 45±11.08 |
| IL-6 in spleens | 142.8±16.07 | 125.2±24.26 | 139.4±26.86 | 118.6±9.30 | 66.5±4.66 | 113.5±41.02 |
| IL-6 in LNs | 10.25±2.56 | 19.5±4.01 | 57.25±14.99 | 21±2.48 | 9.75±1.38 | 77.75±10.91 |
| SARS-CoV-2 viral RNA | | | | | | |
| Probe-V-nCoV2019-S in spleens | undetected | 72.18±10.03 | undetected | undetected | 61.2±10.13 | 77.5±10.91 |
| Probe-V-nCoV2019-S in LNs | undetected | 17.5±6.05 | undetected | undetected | 10.2±3.48 | 77.5±10.91 |
| Probe-V-nCoV2019-S-sense in spleens | 85.4±12.11 | undetected | undetected | undetected | 65.2±6.36 | 93.6±4.27 |
| Probe-V-nCoV2019-S-sense in LNs | 10.5±5.31 | undetected | undetected | undetected | 9.35±4.27 | 93.6±4.27 |
| Viral particles by TEM | Yes | Yes | Yes | Yes | Yes | Yes |

yr, years; WP, White pulp; GC, Germinal center; LN, Lymph node; TEM, Transmission Electron Microscope.  
# Expression levels: Negative: -; Moderate: ++; Severe: +++; Extremely severe: ++++.  
Viral NP antigen was detected by anti-SARS NP antibodies (clone ID: 019, rabbit IgG; Sino Biological).

in controls (Figure 1C). Immunofluorescent double staining illustrated that Fas was expressed on the surface of CD3+ T cells and B220+ B cells in the hilar LNs from COVID-19 autopsies (Figure 1D), suggesting that SARS-CoV-2 promotes Fas-mediated T and B cell apoptosis in spleens and LNs.

Identification of SARS-CoV-2 RNA and Coronavirus-Like Particles in Spleens and LNs

To confirm that SARS-CoV-2 directly infects human spleens and LNs, leading to lymphocyte depletion in vivo, RNA ISH was performed using RNAscope probes directed against the SARS-CoV-2 S gene, targeting 21631–23303 of NC_045512.2 base pairs (RNAscope® Probe-V-nCoV2019-S, #845701, ACD, Newark, CA), and RNAscope® Probe-V-nCoV2019-S-sense (#845701, ACD). Results showed that spleen and hilar LN tissues from COVID-19 autopsies manifested positive signals for Probe-V-nCoV2019-S. In spleens, the positive cells were distributed throughout the whole tissue, especially in red pulp, whereas in the hilar LNs, the positive reaction was found primarily in cells within marginal sinus of the lymph nodules, demonstrating that SARS-CoV-2 directly infects some cells within human spleens and LNs. Interestingly, cells in the spleens and hilar LNs were also positive for Probe-V-nCoV2019-S-sense, illustrating that SARS-CoV-2 has the capacity to replicate in vivo. Here a negative control probe to the bacterial gene diaminopimelate B (DapB) and a positive control probe for RNA integrity to the housekeeping gene peptidylprolyl isomerase B (PPIB) were also included (Figure 2A, Table 2). However, the spleens from trauma victims were negative for Probe-V-nCoV2019-S (Figure S4). Collectively, these data demonstrate that SARS-CoV-2 directly infects some cells in human spleens and LNs.

We next investigated whether human secondary lymphoid organs have SARS-CoV-2 virus by transmission electron microscope (TEM) assay. Two hilar LNs of 1.0–1.5 cm in diameter from two autopsies of COVID-19 subjects (Case #2 and #6) were used to detect virions. The results showed that cells in both hilar LNs were markedly swollen with an expansion of mitochondria and lysosomes. The rough endoplasmic reticulum (RER) and smooth endoplasmic reticulum (SER) were also dilated significantly. Interestingly, coronavirus-like particles were identified in the cytoplasm. The diameter of the virus-like...
Particles varied from approximately 50~100 nm, the interior of virus particles showed electron-dense granular interiors, which are believed to be nuclear capsid. Moreover, virus-like particles show relative uniformity in size, making them different from endosomal structures or other cell trafficking micro-vesicles (Figure 2B). These combined data confirm that SARS-CoV-2 directly infects human spleens and hilar LNs.

ACE2 Is Expressed by Macrophages and DCs in Spleens and LNs

SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming (11). We then investigated the expression of ACE2 and TMPRSS2 in the spleens and hilar LNs. IHC showed that both ACE2 and TMPRSS2 antigens could be observed in the spleens and LNs.
from COVID-19 autopsies. In the LNs, the expression of ACE2 was mainly on cells within the medulla, especially cells in marginal sinus of the lymph nodules, whereas in the spleens, ACE2+ cells were found primarily in the splenic red pulp. TMPRSS2 has similar expressional characteristics to ACE2 in these tissues. Here the expressions of ACE2 and TMPRSS2 in lung tissues from COVID-19 patients were used as positive controls, and sections incubated with rabbit IgG1 antibodies were used as isotype controls (Figure 3A).

The hilar LNs from COVID-19 autopsies were selected to detect which cell subsets are positive for ACE2, and immunofluorescent double staining showed that ACE2 is expressed by SARS-CoV-2 NP positive cells, CD68+ macrophages and CD11c+ DCs, while it is absent on CD4+ and CD8+ T cells and B220+ B cells (Figure 3B). Lymphoid tissue resident CD169+ macrophages function as gatekeepers that have the capacity to capture blood- and lymph-borne pathogens, and these CD169+ macrophages can also support viral replication (12). Immunofluorescent double staining further confirmed that the ACE2 antigen could be observed on CD169+ macrophages in LNs from COVID-19 autopsies (Figure 3B). Collectively, these results demonstrated that ACE2 is expressed by macrophages and DCs in spleens and LNs.

**SARS-CoV-2 Directly Infects Human Macrophages and DCs**

Our data above demonstrated that only macrophages and DCs within spleens and hilar LNs are positive for ACE2, suggesting SARS-CoV-2 might infect macrophages and DCs in these tissues. To confirm this possibility, peripheral blood mononuclear cells (PBMCs) from normal healthy patients were induced to develop into monocytes-derived macrophages (MDMs) and monocytes-derived DCs (MoDCs) in vitro. The expression of Ace2 and Tmprss2 genes was observed in both kinds of cells (Figure 4A). Immunofluorescent staining also showed that both MDMs and MoDCs are positive for ACE2 protein (Figure 4B). These cells were further infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.1 for 2h, after virus absorption, cells were washed and continuously cultured for additional 24h. Importantly, SARS-CoV-2-infected cells manifested high levels of SARS-CoV-2 NP antigen, whereas mock controls were absent of NP expression (Figure 4B). qPCR confirmed that SARS-CoV-2 viral RNA was present in infected but not mock control cells (Figure 4C). RNA ISH showed that cells with SARS-CoV-2 rather mock controls had strong viral RNA, however, the fact that Probe-V-nCoV2019-S-sense was negative in infected cells indicated SARS-CoV-2 might not be able to replicate in MDMs and MoDCs in vitro (Figure 4D). Our current result was similar to Yuen’s observations (13), suggesting that MDMs and MoDCs are susceptible to SARS-CoV-2 infection but seem to disrupt the effective replication of infectious virus.

We next examined whether SARS-CoV-2 infects macrophages and DCs in spleens and LNs in vivo, and the expression of SARS-CoV-2 specific NP and S antigens was examined. Two clones of anti-SARS-CoV-2 NP antibodies (#clone ID: 019, Rabbit polyclonal antibodies, Sino Biological, Beijing, China; #ab273434, mouse monoclonal 6H3, Abcam, Cambridge, UK) and one clone of an anti-SARS-CoV-2 S
antibody (#ab273433, mouse monoclonal 1A9, Abcam) are commercially available at this time. IHC showed that both SARS-CoV-2 NP and S antigens were present in the spleens and hilar LNs of all six COVID-19 autopsies. In the spleen, viral NP+ cells were primarily distributed in the red pulp, whereas positive cells were occasionally observed in white pulp. In the LNs, the SARS-CoV-2 NP+ cells were primarily seen in cells within the marginal sinus of the lymph nodules, and NP+ cells were seldom found in germinal centers (Figure 4D). By contrast, SARS-CoV-2 NP and S antigens were absent in sections from trauma victims, and HBV-ACLF and EBV-infected patients (Figure S5). SARS-CoV-2 NP+ cells in the red pulp of spleens and in the marginal sinus of the lymph nodules of hilar LNs from each fatal COVID-19 cases were calculated by Image-Pro Plus software, and the results were showed in Table 2.

We then performed additional staining to identify the cell types that were positive for SARS-CoV-2. Immunofluorescent double staining of LNs from COVID-19 autopsies confirmed that the majority of SARS-CoV-2 NP antigen is found in ACE2+ cells, including CD68+ and CD169+ macrophages and CD11c+ DCs, whereas CD3+ T cells and B220+ B cells were negative for NP protein (Figure 4E), demonstrating that SARS-CoV-2 directly infects DCs and macrophages in spleens and LNs.

**SARS-CoV-2 Triggers IL-6 and IL-1β Production by Macrophages and DCs**

Our data above showed that these deceased COVID-19 patients had higher serum levels of some pro-inflammatory cytokines (Table 1), however, the original source of these cytokines is unclear. We speculated whether SARS-CoV-2 can directly trigger cytokine secretion from infected cells. MDMs and MoDCs were infected with SARS-CoV-2 (MOI=0.1, 2h) in vitro and cells were collected after 24h to detect the transcription of pro-inflammatory genes. Interestingly, qRT-PCR showed that both macrophages and DCs had significantly higher levels of Il6, Il8 and Il1b gene transcription than mock infected controls. SARS-CoV-2 also promoted the transcription of Tnfa in MoDCs, but not MDMs. By contrast, the transcription of type-I interferons (IFN-I), like Ifna and Ifnb, was dramatically deceased in infected cells compared to mock cells (Figures 5A, B), suggesting that SARS-CoV-2 can promote the transcription of Il6, Il8 and Il1b in both DCs and macrophages.
Pro-inflammatory cytokines IL-6 and IL-1β can induce cell apoptosis and pyroptosis, thus they may accelerate lymphocyte depletion in vivo. We next examined whether SARS-CoV-2 infection induces the expression of IL-6 and IL-1β in spleens and hilar LNs. IHC showed that high levels of IL-6 and IL-1β could be observed in the spleens and the LNs from COVID-19 autopsies, whereas, sections from trauma victims were absent of IL-6 and IL-1β expression (Figure 5C, Table 2). Immunofluorescent double staining showed that IL-6 and IL-1β are primarily produced by SARS-CoV-2 NP+ cells, including CD68+/CD169+ macrophages and CD11c+ DCs (Figures 5D, E). Collectively, these results suggest that SARS-CoV-2 can trigger macrophages and DCs to secrete IL-6 and IL-1β, which might directly decimate lymphocytes following infection in vivo.

**DISCUSSION**

Lymphocytopenia is one of the most prominent clinical presentations of immune damage caused by SARS-CoV, Middle East Respiratory Syndrome (MERS)-CoV and SARS-CoV-2 infection. SARS-CoV has been shown to significantly decrease CD4+ and CD8+ T cell counts by inducing inflammation, whereas, MERS-CoV has been illustrated to efficiently infect T cells and induce T cell apoptosis leading to lymphocytopenia (14–16). We here retrospectively reviewed the clinical and immunological data of 18 fatal COVID-19 cases, and the results showed that these patients had severe lymphocytopenia together with high serum concentrations of inflammatory cytokines IL-6, IL-8 and IL-10. Many routine laboratory tests, such as ferritin, lactate dehydrogenase and D-dimer, were elevated in severe and extremely severe COVID-19 patients (17). Similar to this work, high D-dimer levels were observed in all perished COVID-19 patients, reflecting a hypercoagulable state within these patients. Fourteen cases of these fatal patients also manifested higher urea levels compared to normal values, suggesting that SARS-CoV-2 affects renal function. Moreover, over 90% of these perished patients had increased α-hydroxybutyrate dehydrogenase, lactate dehydrogenase and creatine kinase activity, demonstrating that SARS-CoV-2 triggers myocardial injury. Alanine aminotransferase activity and aspartate aminotransferase activity were used to evaluate liver function, and we found 5 cases of these patients have liver function injury due to very high concentration of these mediators. Collectively, these data demonstrated that the cause of COVID-19 patients’ death is due to SARS-CoV-2-mediated multiple organ damage, cytokine storm and lymphocytopenia.

SARS-CoV-2 mainly transmits into the lung through respiratory tracts, it also distributes to heart, vessels, liver and kidney etc. A pathological report of three COVID-19 cases by minimal invasive autopsies illustrated that decreased numbers of lymphocytes, cell degeneration and necrosis were observed in the infected spleens (18). Another study showed that SARS-CoV-2 infection induces hemophagocytic lymphohistiocytosis (19), suggesting that spleen and LNs may be directly attacked by SARS-CoV-2. The present results from 6 cases of COVID-19 autopsies showed that SARS-CoV-2 viral RNA and coronavirus-like particles could be seen in the spleens and hilar LNs. Interestingly, in situ immunohistochemistry illustrated that
SARS-CoV-2 NP and S antigens were observed in cells within spleens and hilar LNs. Immunofluorescent double staining further demonstrated that SARS-CoV-2 NP antigen was restricted to ACE2-positive macrophages and DCs within spleens and LNs in vivo, suggesting that SARS-CoV-2 may employ ACE2 receptor to facilitate viral entry into macrophages and DCs. To the best of our knowledge, this is the first report of SARS-CoV-2 directly infecting human secondary lymphoid organs. Recent work of Wang et al. revealed that SARS-CoV-2 can infect T cells, although its ability to replicate in T cells is still inconclusive (20). However, we did not find that T or B cells were positive for ACE2, and SARS-CoV-2 NP antigen was absent from T and B cells, demonstrating that this virus does not have the capacity to directly infect and decimate lymphocytes in secondary lymphoid organs.

Innate immune cells in spleens undergo reorganization into “hierarchical clusters” that allow for the initiation and progression of an effective immune response against infections. Macrophages and DCs are sentinel cells for innate and adaptive immunity that affect the pathogenesis of SARS-CoV and MERS-CoV infection (21, 22). Furthermore, macrophages expressing high levels of CD169 (Siglec-1 or sialoadhesin), constitute a minor macrophage population present in lymphoid tissues. CD169+ macrophages are situated on top of B cell follicles, bordering the marginal sinus in the spleen and the subcapsular sinus (SCS) in the LNs, where they are also known as metallophilic marginal zone macrophages and SCS macrophages, respectively (23). The role of CD169+ macrophages as efficient gatekeepers has been demonstrated in a large number of viral infections. Paradoxically, CD169+ macrophages can also support viral replication. Enforced viral replication within CD169+ macrophages endowed them with the distinct feature of being a source of viral antigen (24). We next sought to investigate which cells could potentially contribute to SARS-CoV-2 transport and replication in spleens and LNs, and results showed that SARS-CoV-2 NP also deposited in CD169+ macrophages. Previous work has showed that CD169+ macrophages are the first cell type in the spleen and LNs to bind to particulate antigens and pathogens and function as a filter to remove foreign particles from the lymph fluid and blood (25), we therefore speculated that the CD169+ macrophages contribute to SARS-CoV-2 growth and spread in spleens and LNs in vivo.

We presently showed that the spleen and hilar LN tissues from COVID-19 autopsies manifested severe atrophy and lymphocyte reduction, lymphoid follicles are atrophied, decreased or absent, these results are similar to previously reported literatures (26, 27). Apoptosis-induced lymphocytopenia has been associated with a higher risk of infection and mortality in various clinical settings. For example, MERS-CoV could directly infect human primary T lymphocytes and induce T cell apoptosis (28). Here although the levels of Fas in spleens and hilar LNs from COVID-19 post-mortems are similar to those in tissues from age-matched controls, the expression of Fas is dramatically higher in secondary lymphoid organs from COVID-19 autopsies, suggesting that increased T cell apoptosis is one of the mechanisms responsible for systemic lymphocytopenia following SARS-CoV-2 infection. Dysregulated innate immune response with uncontrolled cytokine production is the most prominent clinical feature aggravating severe COVID-19 disease. Extravagant pro-inflammatory cytokines like IL-6 and IL-1β has been shown to mediate pyroptosis, a proinflammatory form of cell apoptosis (29). Here IHC confirmed that SARS-CoV-2 infected macrophages and DCs in spleens and LNs release high level of IL-6 and IL-1β, which can promote pro-apoptotic Fas upregulation (30). IL-10 is an inhibitory cytokine that not only induces T cell exhaustion, but also mediates cell apoptosis. Importantly, targeting tumors with IL-10 successfully prevents DCs-mediated CD8+ T Cell apoptosis (31). We here showed that 50.0% (9/18) perished COVID-19 cases have higher level of serum IL-10 than normal values, suggesting IL-10 might also involve in mediating lymphocytopenia. Additionally, CRP also has a major role in the apoptotic process. CRP stimulates the production of pro-apoptotic cytokines and inflammatory mediators, including IL-1β, TNF-α, and reactive oxygen species (ROS), via the activation of Fc-γ receptors (32). In the early stages of COVID-19, CRP levels were positively correlated with lung lesions and could reflect disease severity (33, 34). Here we showed that all of these patients had high serum concentrations of CRP (Table 1). These combined data suggested that both cytokine storm and CRP might be involved in inducing lymphocytopenia following SARS-CoV-2 infection.

Our previous work has demonstrated that serum concentrations of IL-6 are negatively correlated with circulating CD4+ and CD8+ T cell counts in COVID-19 patients (3), but little is known about the source of IL-6. We here showed that SARS-CoV-2 effectively triggered the transcription of Il6 from infected MDMs and MoDCs, suggesting these viral infected immune cells are the major source of IL-6. SARS-CoV-2 infection has been shown to elevate mitochondrial ROS and glycolysis by stabilizing hypoxia inducible factor-1α (HIF-1α), which is necessary for viral replication and Il6 transcription in monocytes (35), whether SARS-CoV-2 also hijacks HIF-1α/Glycolysis-dependent axis to promote viral replication and IL-6 secretion from DCs and macrophages need investigation. Tocilizumab, a humanized anti-IL-6 receptor antibody, has been approved for the treatment of COVID-19 patients, and results showed that it can alleviate clinical inflammatory response and efficiently enhance circulating lymphocyte counts (36). However, whether tocilizumab can restore lymphocyte counts in spleens and LNs of COVID-19 patients is an area requiring further investigation. Although data suggest that lymphocytopenia is probably caused by the translocation of lymphocytes from the peripheral blood to the lungs, the exact mechanism by which factors that induce lymphocyte translocation are unclear. IL-8, a potent neutrophil and T cell attractant and activator, plays a critical role in acute lung injury (37). Enhancement of IL-8 level was also reported in perished COVID-19 cases was 22.01 folds above the ULN (Table 1), further study is need to confirm whether IL-8 involves in mediating lymphocyte translocation.

We acknowledge that our study has several limitations. First, the number of patients in this study is relatively small, and the results should be validated in another prospective study. Second, there was no isolation of infectious SARS-CoV-2 virus and no quantification of viral genomes from the spleen or LN tissues due to the limits of the detection kits available now. Third, we found...
that SARS-CoV-2 infection can inhibit the transcription of IFN-I genes (Ifna and Ifnb), which is one of the major innate immune mechanisms against invading viral pathogens. However, the exact mechanisms underlying how SARS-CoV-2 disables these gene transcriptions are still unclear, although one study has shown that SARS-CoV-2 N protein antagonizes IFN-I signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2 (39). Fourth, we here only evaluated mRNA levels of Il6 and Il1b from SARS-CoV-2 infected MDMs and MoDCs by qRT-PCR, the amount of IL-6 and IL-1β in cultured supernatants which were inactivated by β-Propiolactone, however, is unsuccessfully detected by ELISA. Finally, we cannot exclude the possibility that some of the lymphocytopenia may be worsened due to the use of steroids during hospitalization, and further researches are required to determine the effects of corticosteroids on lymphocytes in the context of COVID-19.

In conclusion, we demonstrated that the SARS-CoV-2 virus can directly infect macrophages and DCs in human LNs and spleens, which leads to tissue damage and lymphocyte reduction through the promotion of IL-6 and IL-1β secretion. We also showed that CD169⁺ macrophages and CD11c⁺ DCs might play a central role in mediating SARS-CoV-2 translocation. Mechanistically, SARS-CoV-2 induces lymphocyte depletion in spleens and LNs by inducing Fas/FasL-dependent cell apoptosis, in addition to persistent viral antigen stimulation.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by The Ethics Commission of the Jinyintan Hospital (KY-2020-15.01). The patients/participants provided their written informed consent to participate in this study.

**REFERENCES**

1. Mohammadi A, Esmaeilzadeh E, Li Y, Bosch RJ, Li JZ. SARS-CoV-2 detection in different respiratory sites: A systematic review and meta-analysis. EBioMedicine (2020) 59:102903. doi: 10.1016/j.ebiom.2020.102903

2. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med (2020) 382:929–36. doi: 10.1056/NEJMoas2001191

3. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol (2020) 11:827. doi: 10.3389/fimmu.2020.00827

4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA (2020) 323:1061–9. doi: 10.1001/jama.2020.1585

5. Zou X, Chen K, Zhou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med (2020) 14:185–92. doi: 10.1007/s11684-020-0754-0

6. Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun (2020) 526:135–40. doi: 10.1016/j.bbrc.2020.03.044

7. Li J, Diao B, Guo S, Huang X, Yang C, Feng Z, et al. VSIG4 inhibits proinflammatory macrophage activation by reprogramming mitochondrial pyruvate metabolism. Nat Commun (2017) 8:1322. doi: 10.1038/s41467-017-01327-4

8. Zheng H, Li H, Guo L, Liang Y, Li J, Wang X, et al. Virulence and pathogenesis of SARS-CoV-2 infection in rhesus macaques: A nonhuman primate model of COVID-19 progression. PLoS Pathog (2020) 16:e1008949. doi: 10.1371/journal.ppat.1008949

9. Clark E, Guilpain P, Filip IL, Pansu N, Bihan C, Cartron G, et al. Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. Br J Haematol (2020) 190:e154–6. doi: 10.1111/bjh.16981

10. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity (2009) 30:180–92. doi: 10.1016/j.immuni.2009.01.001

11. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is...
26. Falasca L, Nardacci R, Colombo D, Lalle E, Caro AD, Nicastri E, et al. Post-transcriptional regulation of SARS-CoV-2 in human dendritic cells is associated with viral antagonism of STAT1 phosphorylation. J Infect Dis (2020) 222:734–45. doi: 10.1093/infdis/jiaa356
27. Xu X, Chang XN, Pan HX, Su H, Huang B, Yang M, et al. Pathological changes of the spleen in ten patients with coronavirus disease 2019 (COVID-19) by postmortem needle autopsy. Zhonghua Bing Li Xue Za Zhi (2020) 49:576–82. doi: 10.3760/cma.j.nice12151-20200401-00278
28. Chu H, Zhou J, Wong BH, Li C, Chan JF, Cheng ZS, et al. Middle East Respiratory Syndrome Coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways. J Infect Dis (2016) 213:904–14. doi: 10.1093/infdis/jiv380
29. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol (2009) 7:99–109. doi: 10.1038/nrmicro2070
31. Gau D, Zang B, Zheng J, Gao Z, Zhong Y, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med (2005) 202:415–24. doi: 10.1084/jem.20050828
32. Prilutskiy A, Kritselis M, Shevtsov A, Yambayev I, Vadlamudi C, Zhao Q, et al. Eosinopenia and elevated C-reactive protein and inflammation: conformational changes affect function. Biol Chem (2015) 396:1181–97. doi: 10.1515/hsz-2015-0149
33. Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. J Med Virol (2020) 92(10):1733–4. doi: 10.1002/jmv.25819
34. Li Q, Ding X, Xia G, Chen H, Chen F, Geng Z, et al. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study. EClinicalMedicine (2020) 31:100375. doi: 10.1016/j.eclinm.2020.100375.
35. Codo AC, Davanzo GG, Monteiro LB, Souza GF, Muraro SP, Virgilio-da-Silva JV, et al. Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis. Cell Metab (2020) 32:498–9. doi: 10.1016/j.cmet.2020.06.007
36. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A (2020) 117 (20):10970–5. doi: 10.1073/pnas.2005615117
37. Allen TC, Kudrowiska A. Interleukin 8 and acute lung injury. Arch Pathol Lab Med (2014) 138:266–9. doi: 10.5858/arpa.2013-0182-RA
38. Vassallo M, Manni S, Pini P, Blanchouin E, Tichioni M, Seitz-Polski B, et al. Patients with Covid-19 exhibit different immunological profiles according to their clinical presentation. Int J Infect Dis (2020) 101:174–9. doi: 10.1016/j.ijid.2020.09.1438
39. Mu J, Fang Y, Yang Q, Shu T, Wang A, Huang M, et al. SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2. Cell Discov (2020) 6:65. doi: 10.1038/s41421-020-00280-3

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Xiang, Feng, Diao, Tu, Qiao, Yang, Zhang, Wang, Wang, Liu, Wang, Liu, Chen, Wu and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.